In this issue of Blood, Lu et al describe the cooperation between an orally 
bioavailable mouse double minute 2 (MDM2) antagonist (RG7112) and the pegylated 
interferon α (Peg-IFNα 2a) to target JAK2V617F hematopoietic progenitors and 
stem cells. Their work provides a rationale for the treatment of patients 
suffering from myeloproliferative neoplasms (MPNs).